Vesicular Antibodies A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy

Vesicular Antibodies : A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy

© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Détails bibliographiques
Publié dans:Advanced materials (Deerfield Beach, Fla.). - 1998. - 31(2019), 17 vom: 06. Apr., Seite e1808294
Auteur principal: Liu, Xue (Auteur)
Autres auteurs: Liu, Chao, Zheng, Zizheng, Chen, Siyuan, Pang, Xin, Xiang, Xinchu, Tang, Jixian, Ren, En, Chen, Yuanzhi, You, Min, Wang, Xiaoyong, Chen, Xiaoyuan, Luo, Wenxin, Liu, Gang, Xia, Ningshao
Format: Article en ligne
Langue:English
Publié: 2019
Accès à la collection:Advanced materials (Deerfield Beach, Fla.)
Sujets:Journal Article chemotherapy full-length antibodies immunotherapy membrane nanovesicles theranostics Antibodies, Monoclonal Antigens, Neoplasm Antineoplastic Agents Drug Carriers plus... Photosensitizing Agents Doxorubicin 80168379AG Indocyanine Green IX6J1063HV
Description
Résumé:© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
The ability to selectively kill cancerous cell populations while leaving healthy cells unaffected is a key goal in oncology. The use of nanovesicles (NVs) as chemotherapeutic delivery vehicles has been recently proven successful, yet monotherapy with monomodalities remains a significant limitation for solid tumor treatment. Here, as a proof of principle, a novel cell-membrane-derived NVs that can display full-length monoclonal antibodies (mAbs) is engineered. The high affinity and specificity of mAb for tumor-specific antigens allow these vesicular antibodies (VAs) to selectively deliver a cytotoxic agent to tumor cells and exert potent inhibition effects. These VAs can also regulate the tumor immune microenvironment. They can mediate antibody-dependent cellular cytotoxicity to eradicate tumor cells via recruitment and activation of natural killer cells in the tumor. Upon further encapsulation with chemotherapeutic agents, the VAs show unequaled cooperative effects in chemotherapy and immunotherapy in tumor-bearing mice. As far as it is known, this is the first report of a VA-based multifunctional combination therapy platform. This might lead to additional applications of vesicular antibodies in cancer theranostics
Description:Date Completed 27.11.2019
Date Revised 30.09.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.201808294